Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 10/20 | 0.76 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.71 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | MAPT | P10636 | 1/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | THRB | P10828 | 1/20 | 0.62 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.61 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acefylline SCHEMBL308514 | 0.87 | ADORA2B (1.00) | ADORA2BSMN1; SMN2LMNAMAPTKMT2A | |
| Acefylline SCHEMBL18191994 | 0.87 | ADORA2B (1.00) | ADORA2BSMN1; SMN2LMNAMAPTKMT2A | |
| SCHEMBL11531219 | 0.87 | ADORA2B (0.78) | ADORA2BSMN1; SMN2LMNAMAPTKMT2A | |
| SCHEMBL28405904 | 0.86 | ADORA2B (0.72) | ADORA2BSMN1; SMN2LMNAMAPTKMT2A | |
| Acefylline SCHEMBL8402147 | 0.85 | ADORA2B (0.97) | ADORA2BSMN1; SMN2LMNAMAPTKMT2A | |
| SCHEMBL660023 | 0.85 | ADORA2B (0.76) | ADORA2BSMN1; SMN2LMNAMAPTKMT2A | |
| SCHEMBL10850696 | 0.84 | SMN1; SMN2 (0.82) | ADORA2BSMN1; SMN2LMNAMAPTKMT2A | |
| Acefylline SCHEMBL1477803 | 0.84 | ADORA2B (0.74) | ADORA2BSMN1; SMN2LMNAMAPTKMT2A | |
| SCHEMBL15159794 | 0.83 | ADORA2B (0.72) | ADORA2BSMN1; SMN2LMNAMAPTKMT2A | |
| SCHEMBL15375895 | 0.83 | KMT2A (0.74) | ADORA2BSMN1; SMN2LMNAKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4652568-A | Theophylline-7-acetic acid ester of d,l-trans-sobrerol having mucosecretolytic-fluidizing and antibronchospastic activity, a process for its preparation and pharmaceutical compositions thereof | CAMILLO CORVI S.P.A. (IT) | 1987-03-24 | — | — | US | claimed |
| EP-3134410-B1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | LILLY CO ELI (US) | 2021-03-10 | — | — | EP | disclosed |
| EP-3134410-B1 | INHIBITING THE TRANSIENT RECEPTOR POTENTIAL A1 ION CHANNEL | LILLY CO ELI (US) | 2021-03-10 | — | — | EP | disclosed |
| US-10428072-B2 | Inhibiting the transient receptor potential A1 ion channel | ELI LILLY AND COMPANY (US) | 2019-10-01 | — | — | US | disclosed |
| US-10428072-B2 | Inhibiting the transient receptor potential A1 ion channel | ELI LILLY AND COMPANY (US) | 2019-10-01 | — | — | US | disclosed |
| US-10351567-B2 | Methods and compositions for treating pain | ELI LILLY AND COMPANY (US) | 2019-07-16 | — | — | US | disclosed |
| US-20180093986-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | HYDRA BIOSCIENCES, INC. (US) | 2018-04-05 | — | — | US | disclosed |
| US-20180093986-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | HYDRA BIOSCIENCES, INC. (US) | 2018-04-05 | — | — | US | disclosed |
| US-9815838-B2 | Methods and compositions for treating pain | HYDRA BIOSCIENCES, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| US-9815838-B2 | Methods and compositions for treating pain | HYDRA BIOSCIENCES, INC. (US) | 2017-11-14 | — | — | US | disclosed |
| WO-1989010744-A1 | NEUROLOGICALLY ACTIVE COMPOUNDS | NAFTCHI N ERIC (US) | 1989-11-16 | — | — | WO | disclosed |
| EP-0157284-B1 | THEOPHYLLINE-7-ACETIC ACID ESTER OF D,L-TRANS-SOBREROL HAVING MUCOSECRETOLYTIC-FLUIDIZING AND ANTIBRONCHOSPASTIC ACTIVITY, A PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITIONS THEREOF | CAMILLO CORVI S.p.A. (IT) | 1989-08-09 | — | — | EP | disclosed |
| EP-0089028-B1 | THEOPHYLLIN DERIVATIVES, AND PROCESS FOR THEIR PREPARATION | CHINOIN Gyogyszer és Vegyészeti Termékek Gyára RT. (HU) | 1988-05-25 | — | — | EP | disclosed |
| US-4652568-A | Theophylline-7-acetic acid ester of d,l-trans-sobrerol having mucosecretolytic-fluidizing and antibronchospastic activity, a process for its preparation and pharmaceutical compositions thereof | CAMILLO CORVI S.P.A. (IT) | 1987-03-24 | — | — | US | disclosed |
| US-4652568-A | Theophylline-7-acetic acid ester of d,l-trans-sobrerol having mucosecretolytic-fluidizing and antibronchospastic activity, a process for its preparation and pharmaceutical compositions thereof | CAMILLO CORVI S.P.A. (IT) | 1987-03-24 | — | — | US | disclosed |
| US-4584372-A | Compound 3-(1,2,3,6-tetrahydro-1,3-dimethyl-2,6-dioxopurine-7-acetyl-8-(2-phenylethyl)-1-oxa-3,8-diazaspiro-(4,5)decan-2-one and a process of preparation thereof | VENERO AURELIO O (ES) | 1986-04-22 | — | — | US | disclosed |
| US-4565817-A | ANTITUSSIVE AGENTS | CHINOIN GYOGYSZER-ES VEGYESZETI TERMEKEK GYARA R.T. (HU) | 1986-01-21 | — | — | US | disclosed |
| EP-0157284-A2 | Theophylline-7-acetic acid ester of d,l-trans-sobrerol having mucosecretolytic-fluidizing and antibronchospastic activity, a process for its preparation and pharmaceutical compositions thereof | CAMILLO CORVI S.p.A. (IT) | 1985-10-09 | — | — | EP | disclosed |
| EP-0157284-A2 | Theophylline-7-acetic acid ester of d,l-trans-sobrerol having mucosecretolytic-fluidizing and antibronchospastic activity, a process for its preparation and pharmaceutical compositions thereof | CAMILLO CORVI S.p.A. (IT) | 1985-10-09 | — | — | EP | disclosed |
| EP-0089028-A1 | Theophyllin derivatives, and process for their preparation | CHINOIN Gyogyszer és Vegyészeti Termékek Gyára RT. (HU) | 1983-09-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10428072-B2 | Inhibiting the transient receptor potential A1 ion channel | TRPA1, TRPV1, TRPV2 | ADORA2B 161/4885SMN1; SMN2 713/4885LMNA 2100/4885 |
| US-10351567-B2 | Methods and compositions for treating pain | ACHE, COL2A1, MMP8 | ADORA2B 493/4885SMN1; SMN2 365/4885LMNA 1619/4885 |
| US-20180093986-A1 | METHODS AND COMPOSITIONS FOR TREATING PAIN | ACHE, COL2A1, MMP8 | ADORA2B 493/4885SMN1; SMN2 365/4885LMNA 1619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.